Search Results for “AI” – Page 36 – media

The latest domestic innovative COVID-19 drug Taizhongding® is exclusively available on Meituan’s online drug shopping website

On December 28, the innovative COVID-19 drug Taizhongding® developed by Guangsheng Zhonglin Technology Co., Ltd. (hereinafter referred to as Guangsheng Zhonglin), an innovative drug subsidiary of Fujian Guangshengtang Pharmaceuticals, was exclusively launched on the Meituan drug purchase online . It is understood that Taizhongding® is currently the only small molecule antiviral drug in China that widely covers the XBB series of mutant strains. The relevant person in charge of Fujian Guangshengtang Pharmaceutical stated that they chose Meituan Medicine as the online launch channel for Taizhongding® because they hope to cooperate with Meituan Medicine to further enhance the awareness and accessibility of innovative drugs. Give patients in need more treatment options. Search volume for COVID-19 drugs increases, domestic innovative drugs provide new solutions for patients Recently, the new coronavirus variant JN.1 has once again attracted public attention. Authoritative data shows that in early November this year, JN.1 accounted for about 4% ...
- Source: drugdu
- 103
- January 1, 2024
HANSIZHUANG Sets Sail in Indonesia Market

Shanghai, China, December 28, 2023 – Shanghai Henlius Biotech, Inc. (2696.HK) announces that recently, PT Kalbio Global Medika, the subsidiary of Henlius’ partner PT Kalbe Genexine Biologics (KGbio), has received the relevant registration certificates issued by Indonesia’s National Agency for Drug and Food Control (Indonesian: Badan Pengawas Obat and Makanan, the “BPOM”) for the approval of Henlius’ self-developed and manufactured anti-PD-1 mAb HANSIZHUANG (serplulimab) in Indonesia under the trade name Zerpidio® for the treatment of extensive stage small cell lung cancer (ES-SCLC). This is the first time HANSIZHUANG has been successfully approved for marketing in an overseas market, and it has become the first China anti-PD-1 mAb successfully approved for marketing in Southeast Asia. Currently, Henlius is joining hands with KGbio for the development and commercialisation in 22 countries, and the approval is expected to bring HANSIZHUANG to more patients in Indonesia. Lung cancer (LC) is one of the most ...
- Source: drugdu
- 353
- December 30, 2023
Organon pays $50M to pick up rights to pair of Eli Lilly migraine meds in Europe

Organon, the women’s health-focused spinoff of Merck, has picked up the rights to distribute and promote a pair of migraine medicines overseas. Monday, Organon unveiled a marketing pact with Eli Lilly to take charge of Emgality and Rayvow in Europe. Emgality is approved to help prevent migraines in adults who have at least four migraine days per month, while Rayvow is cleared for acute treatment of the headache phase of migraine attacks. The commercialization agreement bolsters Organon’s existing suite of central nervous system treatments and furthers the company’s mission to help women, who are disproportionately affected by migraines, Organon’s CEO, Kevin Ali, said in a statement. Under the deal, Lilly will maintain marketing authorizations for its drugs and continue to manufacture the products. In exchange for the rights, Organon is handing over an upfront payment of $50 million. Lilly is also in line to receive other sales-based milestone payouts, the ...
- Source: drugdu
- 170
- December 30, 2023
AI Accurately Predicts Cancer Outcomes from Tissue Samples

Patient tissue samples are commonly examined on slides by pathologists, a process integral to diagnosis. This traditional method, while effective, is notably time-intensive and subject to variability in interpretations among different pathologists. Moreover, some subtle details in pathology images might escape human observation but could hold critical insights into a patient’s health status. Over recent years, several artificial intelligence (AI) models have been developed to undertake certain tasks typically performed by pathologists, such as classifying cell types or gauging cellular interactions based on proximity. Nevertheless, these models have not fully captured the more intricate aspects of tissue image analysis that pathologists conduct, including recognizing complex cell spatial arrangements and filtering out irrelevant image ‘noise’ that could distort interpretations. Addressing this gap, researchers have now introduced an innovative AI model that is capable of examining the spatial organization of cells within tissue samples, offering precise predictions about cancer patient outcomes and ...
- Source: drugdu
- 139
- December 29, 2023
Fosun Diagnostics’ Fully Automated Chemiluminescence Immunoassay Analyzer F-i1000 Obtains EU IVDR Certification

Recently, Fosun Diagnostics announced that its fully automated chemiluminescence immunoassay analyzer, F-i1000, has received approval for EU IVDR CE registration. The issuance of the registration certificate under the IVDR regulation signifies international recognition of the quality of Fosun Diagnostics’ chemiluminescence products and the ability to meet diverse testing requirements for projects in various levels of medical institutions such as hospitals, core laboratories, and clinics, both domestically and internationally. CE certification is granted based on relevant EU laws, regulations, and standards, serving as a passport for products to freely circulate in the EU market. On May 5, 2017, the EU released the In Vitro Diagnostic Medical Devices Regulation (IVDR) (Regulation (EU) 2017/746), replacing the original EU In Vitro Diagnostic Medical Devices Directive (IVDD, Directive 98/79/EC). After the transition period following the regulation’s implementation, in vitro diagnostic medical devices without IVDR CE certification will no longer be allowed to enter the EU ...
- Source: drugdu
- 105
- December 29, 2023
With FDA approval, Ionis and AstraZeneca gear up to launch rare disease drug Wainua

Ionis Pharmaceuticals and AstraZeneca are wrapping up the year with a much-anticipated present from the FDA: an approval for the companies’ transthyretin amyloidosis (ATTR) drug Wainua. More specifically, the agency signed off on the ligand-conjugated antisense oligonucleotide (LICA) drug to treat polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (ATTRv-PN), a rare and often fatal disease that affects 40,000 people globally, the companies said in a press release. The nod was backed by phase 3 data showing Wainua’s ability to provide “consistent and sustained” benefit in outcomes measures, including serum transthyretin concentration and neuropathy impairment, as well as improvements in quality of life. Crucially, Wainua comes in an auto-injector form that patients can administer themselves once a month. That gives the treatment a convenience edge against the competition, including Alnylam’s Onpattro, which is delivered subcutaneously at treatment centers. Despite the Alnylam option, the unmet need for the genetic disease remains ...
- Source: drugdu
- 222
- December 27, 2023
da Vinci Innovation & Training Center Celebrates its Second Anniversary

The da Vinci Innovation & Training Center marks its second anniversary. Over the past two years, the center has provided more than 1,300 training sessions for healthcare professionals and conducted training operations related to da Vinci technology and surgeries for over 3,000 clinical nursing staff. Equipped with various series of da Vinci surgical robots and the Ion Bronchoscope Operation Control System (not yet launched in China), the da Vinci Innovation & Training Center features a surgical operating room capable of simultaneous training and operations for six da Vinci surgeries, an Ion simulation operating room, a training classroom for 40 people, and cutting-edge simulation training equipment, linked surgical beds, energy platforms, anesthesia machines, and other medical devices. Additionally, it includes multimedia conference rooms, a restaurant, a refreshment area, a maternity room, and changing rooms. Medical professionals can learn cutting-edge minimally invasive instruments and diagnostic techniques in such a simulated clinical environment. ...
- Source: drugdu
- 105
- December 27, 2023
The AI Tool that Matters Most for Clinical Care Isn’t ChatGPT

The excitement for artificial intelligence (AI) use cases in healthcare—especially those involving generative AI and ChatGPT—is palpable, with experts predicting generative AI could help unlock $1 trillion in healthcare savings. However the AI solution that holds the strongest potential to strengthen care outcomes and health equity isn’t the one healthcare leaders think of first. Instead, right-now value could come from extractive AI. It’s a tool that gives organizations the power to put even handwritten text sent via images or PDF by digital fax into a structured data play. It’s also a practical solution for advancing data interoperability without a heavy technology lift to include healthcare’s “digital have-nots,” like post-acute care facilities and health clinics. A powerful lever for improving health equity A healthcare organization’s ability to support total care, especially for our nation’s most vulnerable patient populations, depends on access to data that enables a 360-degree view of the patient’s ...
- Source: drugdu
- 116
- December 25, 2023
Previously unrecognized class of antibodies can broadly neutralize multiple virus strains

Researchers have identified a previously unrecognized class of antibodies-;immune system proteins that protect against disease-;that appear capable of neutralizing multiple forms of flu virus. These findings, which could contribute to development of more broadly protective flu vaccines, will publish December 21st by Holly Simmons of the University of Pittsburgh School of Medicine, US, and colleagues in the open access journal PLOS Biology. A flu vaccine prompts the immune system to make antibodies that can bind to a viral protein called hemagglutinin on the outside of an invading flu virus, blocking it from entering a person’s cells. Different antibodies bind to different parts of hemagglutinin in different ways, and hemagglutinin itself evolves over time, resulting in the emergence of new flu strains that can evade old antibodies. New flu vaccines are offered each year based on predictions of whatever the most dominant strains will be. Extensive research efforts are paving the ...
- Source: drugdu
- 215
- December 25, 2023
Shanghai RAAS Cancels Limited Payment Scope of Medical Insurance for Some Products

According to the official website of the State Medical Insurance Bureau, in order to further improve the level of medication protection for the insured, in accordance with the Interim Measures for the Administration of Medicines for Basic Medical Insurance and the Requirements of the Work Program for Adjustment of the National Drug Catalogs for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance for the Year of 2023, the State Medical Insurance Bureau and the Ministry of Human Resources and Social Security have organized to adjust and formulate the “Drug Catalog (2023)” for the National Drug Catalog (2023)”, which was officially implemented from January 1, 2024 onwards. This catalog includes human albumin, IVIG (intravenous human immunoglobulin), human fibrinogen, human plasminogen complex, human coagulation factor VIII, human coagulation factor IX, human immunoglobulin, tetanus human immunoglobulin, human rabies immunoglobulin, and recombinant human coagulation factor VIIa, recombinant human coagulation factor VIII, and recombinant ...
- Source: drugdu
- 83
- December 25, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.